{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:49:33Z","timestamp":1792054173287,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.psychres.2026.117266","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:25:16Z","timestamp":1781105116000},"page":"117266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine"],"prefix":"10.1016","volume":"364","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-3840","authenticated-orcid":false,"given":"Rune Andreas","family":"Kroken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Alisauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liss G\u00f8ril","family":"Anda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bartz-Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan \u00d8ystein","family":"Berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-5092","authenticated-orcid":false,"given":"Jill","family":"Bjarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-1337","authenticated-orcid":false,"given":"Farivar","family":"Fathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hugdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-2336","authenticated-orcid":false,"given":"Inge","family":"Joa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-7971","authenticated-orcid":false,"given":"Eirik","family":"Kjelby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Ketil","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-5067","authenticated-orcid":false,"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8452-3760","authenticated-orcid":false,"given":"Ieva","family":"Ratke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igne","family":"Sinkeviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Stabell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar Martin","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-8357","authenticated-orcid":false,"given":"Anja","family":"Torsvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig Kl\u00e6bo","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.psychres.2026.117266_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the calgary depression scale","volume":"163","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.psychres.2026.117266_bib0011","unstructured":"Antipsychotic Drugs Market Size, Companies and Growth. towardshealthcare.com (accessed 7 October 2024)."},{"issue":"3","key":"10.1016\/j.psychres.2026.117266_bib0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S1461145705005808","article-title":"The effects of celecoxib augmentation on cytokine levels in schizophrenia","volume":"9","author":"Bresee","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2026.117266_bib0034","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/pharmrev.122.000618","article-title":"Dopamine, immunity, and disease","volume":"75","author":"Channer","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.psychres.2026.117266_bib0044","series-title":"Statistical Power Analysis for the Behavioral Sciences 2ed ed","author":"Cohen","year":"1988"},{"issue":"2","key":"10.1016\/j.psychres.2026.117266_bib0041","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.psychres.2006.08.005","article-title":"Interleukin-12 plasma levels in drug-na\u00efve patients with a first episode of psychosis: effects of antipsychotic drugs","volume":"158","author":"Crespo-Facorro","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2026.117266_bib0039","series-title":"The Cytokines of the Immune System - the Role of Cytokines in Disease Related to Immune Response","author":"Dembic","year":"2015"},{"key":"10.1016\/j.psychres.2026.117266_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2024.06.047","article-title":"Remission in schizophrenia spectrum disorders: a randomized trial of amisulpride, aripiprazole and olanzapine","volume":"271","author":"Drosos","year":"2024","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2026.117266_bib0032","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/schbul\/sbaa190","article-title":"Classification of psychoses based on immunological features: a machine learning study in a large cohort of first-episode and chronic patients","volume":"47","author":"Enrico","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.psychres.2026.117266_bib0007","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.biopsych.2013.01.001","article-title":"Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia","volume":"73","author":"Fineberg","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0035","article-title":"Immunomodulatory effects of amisulpride on mammalian macrophages","author":"G\u00fcrcan","year":"2025","journal-title":"Ir. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.psychres.2026.117266_bib0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.psychres.2026.117266_bib0038","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187152809787582507","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders","volume":"8","author":"Gee","year":"2009","journal-title":"Inflamm. Allergy Drug Targets"},{"issue":"12","key":"10.1016\/j.psychres.2026.117266_bib0019","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin. sci. (Lond. Engl.: 1979)"},{"issue":"3","key":"10.1016\/j.psychres.2026.117266_bib0018","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0030","series-title":"Assessment Manual for Psychopharmacology - Revisited","author":"Guy","year":"1976"},{"issue":"4","key":"10.1016\/j.psychres.2026.117266_bib0004","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2215-0366(23)00025-1","article-title":"Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis","volume":"10","author":"Halstead","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117266_bib0002","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1176\/appi.ajp.2011.11030459","article-title":"Long-term Follow-Up of the TIPS Early Detection in Psychosis Study; Effects on 10-Year Outcome","volume":"169","author":"Hegelstad","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0042","article-title":"Association between cytokines and suicidality in patients with psychosis: A multicentre longitudinal analysis","volume":"37","author":"Hoprekstad","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"issue":"3","key":"10.1016\/j.psychres.2026.117266_bib0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"10202","key":"10.1016\/j.psychres.2026.117266_bib0012","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.psychres.2026.117266_bib0022","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2018.06.039","article-title":"Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-na\u00efve first episode psychosis individuals: A 3 months randomized study","volume":"202","author":"Juncal-Ruiz","year":"2018","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.psychres.2026.117266_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd11070206","article-title":"Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular diseases","volume":"11","author":"Katkenov","year":"2024","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"2","key":"10.1016\/j.psychres.2026.117266_bib0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2026.117266_bib0028","series-title":"Assessment and Research","article-title":"Positive and negative syndroms in schizophrenia","author":"Kay","year":"1991"},{"issue":"11","key":"10.1016\/j.psychres.2026.117266_bib0016","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/pharmaceutics11110585","article-title":"Conjugation of Amisulpride, an anti-psychotic agent, with 5-aminosalicylic acid via an AZO bond yields an orally active mutual prodrug against rat colitis","volume":"11","author":"Kim","year":"2019","journal-title":"Pharmaceutics."},{"issue":"753","key":"10.1016\/j.psychres.2026.117266_bib0051","article-title":"Constructing the immune signature of schizophrenia for clinical use and research","volume":"9","author":"Kroken","year":"2019","journal-title":"Integr. Rev. Transl. Descr. Diagn."},{"issue":"4","key":"10.1016\/j.psychres.2026.117266_bib0047","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/acps.13076","article-title":"Increased mortality from somatic multimorbidity in patients with schizophrenia: a Danish nationwide cohort study","volume":"140","author":"Kugathasan","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2026.117266_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euroneuro.2025.07.011","article-title":"Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction","volume":"99","author":"Lange-Asschenfeldt","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2026.117266_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024597","article-title":"Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder","volume":"6","author":"Laursen","year":"2011","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.psychres.2026.117266_bib0031","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","article-title":"Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects","volume":"73","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2019_91","article-title":"Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia","author":"Pandurangi","year":"2019","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.psychres.2026.117266_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165024","article-title":"Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis","volume":"8","author":"Papadopoulou","year":"2023","journal-title":"JCI. Insight."},{"issue":"1","key":"10.1016\/j.psychres.2026.117266_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications","volume":"20","author":"Penninx","year":"2018","journal-title":"Dialogues. Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.psychres.2026.117266_bib0027","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.7.27","article-title":"Risks and challenges in interpreting simultaneous analyses of multiple cytokines","volume":"9","author":"Pfister","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"6","key":"10.1016\/j.psychres.2026.117266_bib0001","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41380-018-0058-9","article-title":"Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models","volume":"24","author":"Pillinger","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0052","article-title":"Sex differences in the peripheral levels of cytokines during 12-month antipsychotic treatment in a drug-na\u00efve schizophrenia spectrum cohort","volume":"44","author":"Ratke","year":"2025","journal-title":"Brain Behav. Immun. - Health"},{"issue":"9","key":"10.1016\/j.psychres.2026.117266_bib0010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ijnp\/pyy062","article-title":"Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis","volume":"21","author":"Romeo","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2026.117266_bib0048","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fca-2021-0027","article-title":"Lessons learned from large cardiovascular outcome trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, Colcot and LoDoCo2)","volume":"17","author":"Samuel","year":"2021","journal-title":"Future cardiol."},{"key":"10.1016\/j.psychres.2026.117266_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.105071","article-title":"Human macrophages stimulate expression of inflammatory mediators in adipocytes; effects of second-generation antipsychotics and glucocorticoids on cellular cross-talk","volume":"125","author":"Sarsenbayeva","year":"2021","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.psychres.2026.117266_bib0023","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2026.117266_bib0043","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2024.11.001","article-title":"Sex-stratified mortality estimates in people with schizophrenia: a systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia","volume":"91","author":"Solmi","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2026.117266_bib0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.psychres.2026.117266_bib0026","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archpsyc.1992.01820080032005","article-title":"The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description","volume":"49","author":"Spitzer","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117266_bib0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpsychires.2018.08.017","article-title":"Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells","volume":"105","author":"Stapel","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2026.117266_bib0049","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117266_bib0037","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.psychres.2026.117266_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/7854_2018_88","article-title":"Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia","volume":"44","author":"Upthegrove","year":"2020","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.psychres.2026.117266_bib0024","series-title":"International Statistical Classification of Diseases and Related Health Problems. 10th Revision","year":"1994"},{"issue":"7","key":"10.1016\/j.psychres.2026.117266_bib0017","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:29:55Z","timestamp":1792052995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S0165178126003264"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117266","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117266"}}